← board
INCR
distress 1/10 · well-funded / low risk$0.94+4%today-46% from 52w high
Revenue
$270M
Liquidity
$48M
Runway
—
Shares 1y
0%
Price & events
+0.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
+3.6%
1D
-1.6%
1W
-13.8%
1M
+16.0%
3M
+0.4%
6M
-40.1%
1Y
-61.8%
2Y
-84.4%
5Y
-26.6%
All
Overview
- Market Cap
- $51.40M
- Enterprise Value
- $64.39M
- Volume
- 12.10K
- 52 Week Range
- $0.73 – $1.73
- Total Shares
- 54.68M
- Float Shares
- 38.04M
- Short %
- 0.03%
- % Held by Insiders
- 39.17%
- % Held by Institutions
- 1.04%
- RVOL
- 0.18x
- Beta
- 0.57
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 54,681,335 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.